Ken Stranigan

Ken Stranigan is an experienced professional in market access and account management, currently serving as the Vice President of Market Access & Account Management at ITM Isotope Technologies Munich SE since April 2025 and as the Vice President of Market Access at Telix Pharmaceuticals Limited since April 2023. Previously, Ken held several leadership roles at Novartis, including Executive Director of Market Access and Account Management for Radioligand Therapy and Executive Director of Market Access for Novartis/AAA. Ken's extensive background includes national leadership positions at Advanced Accelerator Applications and Bayer Oncology, as well as roles in reimbursement strategy at Celleration, Inc., Shire, Ipsen, and Roche. Ken holds a Master's degree in Global Management from the University of Phoenix and a Bachelor's degree in Business Administration from Azusa Pacific University.